Eli Lilly and Company LLY, together with Amylin Pharmaceuticals, Inc. AMLN
and Alkermes, Inc. ALKS, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending approval of exenatide 2 mg powder and solvent for prolonged release suspension for injection in the European Union for the treatment of type 2 diabetes in combination with certain oral therapies. This application to the European regulatory authorities is for use of BYDUREON as a once-weekly 2 mg dose to improve glycemic control in adults who have not achieved adequate glycemic control on maximally tolerated doses of these oral therapies. If approved, BYDUREON would be the first once-weekly type 2 diabetes treatment.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in